^
    9ms
    CSG-301-101: SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies (clinicaltrials.gov)
    P1, N=61, Active, not recruiting, Hangzhou Sumgen Biotech Co., Ltd. | Trial completion date: Dec 2024 --> Jun 2026
    Trial completion date
    |
    CD38 (CD38 Molecule)
    |
    SG301 IV
    over1year
    A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients (clinicaltrials.gov)
    P3, N=360, Recruiting, Hangzhou Sumgen Biotech Co., Ltd.
    New P3 trial • Combination therapy
    |
    pomalidomide • SG301 IV
    over1year
    SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies (clinicaltrials.gov)
    P1, N=61, Active, not recruiting, Hangzhou Sumgen Biotech Co., Ltd. | Withdrawn --> Active, not recruiting | Trial completion date: Oct 2022 --> Dec 2024 | Trial primary completion date: Sep 2022 --> Jun 2024
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    CD38 (CD38 Molecule)
    |
    CD38 expression
    |
    SG301 IV
    over2years
    SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies (clinicaltrials.gov)
    P1, N=0, Withdrawn, Hangzhou Sumgen Biotech Co., Ltd. | N=108 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    CD38 (CD38 Molecule)
    |
    CD38 expression
    |
    SG301 IV
    almost5years
    SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies (clinicaltrials.gov)
    P1, N=108, Not yet recruiting, Hangzhou Sumgen Biotech Co., Ltd.
    Clinical • New P1 trial
    |
    CD38 (CD38 Molecule)
    |
    CD38 expression
    |
    SG301 IV